Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

2011104 citationsJournal Article

Authors

Good health and well-being

Published in: Investigational New Drugs

Volume 30, Issue 3, pp. 1121-1131

Field-Weighted Citation Impact: 4.60